Both selpercatinib and pralsetinib showed durable responses not only in RET-altered thyroid cancers and NSCLCs but also in other malignancies associated with RET mutations (Drilon et al. 2020a, Wirth et al. 2020, Gainor et al. 2021a, Subbiah et al. 2021b, 2022a,b). Here, RET is linked to thyroid cancer.